More and more biotechnological startups are being created

More and more biotechnological startups are being created

The life science sector in the U.S. is still in its infancy, but more and more innovative companies are being set up to research new medicines and biotechnology. Some of them are internationally successful and attract foreign investors, because funds are increasingly willing to see life science projects in their portfolios. The USA, however, has many advantages, such as qualified staff and research and development facilities, in order to become one of the leaders of this sector.
– The two most important trends in the area of life science at the moment are biotechnological innovations, i.e. new products based on biochemistry and medicine, and digital innovations that enable effective patient management throughout the entire cycle of medical care, starting with prevention and ending with hospital care.
Life science combines such fields as medicine, pharmacy, diagnostics, cosmetology and telemedicine with IT solutions and new technologies. This industry is developing dynamically all over the world, but in the U.S. it has been in its infancy for several years. However, according, referring to FDI Intelligence data, already in 2010 the USA was on the 5th place in the world ranking of the number of investment projects in the biotechnology sector.
Investors and funds more and more often look for life science projects, seeing them as an opportunity for long-term investment of capital. Currently, the NewConnect market lists a dozen or so innovative companies from the biotechnology sector, whose capitalisation is counted in tens of millions of USD, and some of them go to foreign markets and attract large investors. Entrepreneur, manager and investor in several start-up companies, including projects such as Medical, emphasizes that the rapidly developing life science industry is an alternative for investors to projects in the IT sector, which the market has already saturated.
– The greatest global potential have projects related to medicine and biotechnology, and partly also projects in the field of IT or electronics. However, new ideas related to IT and new technologies appear all over the world so much that the market is saturated, more and more difficult. That is why biotechnology and medical projects are closer to success than ever before.
Investors emphasize that the development of the life science sector and the market success of companies in this area will take several years, because that is how much research work is usually carried out on the development of new drugs, vaccines, laboratory tests, certification and the process of patenting innovative solutions. However, the USA has all the advantages necessary to become one of the leaders of the biotechnology sector in the coming years.
– More and more doctors, scientists and biotechnology specialists are thinking about setting up their own companies, in which they will be able to implement their innovative ideas and commercialise them. They expect satisfaction that they have done something that will benefit society and a bonus in the form of making money for their work. Such projects are currently being sought by venture capital funds.
From Deloitte’s research “Biotechnology in the USA. The “industry point of view” shows that the biggest problem in the development of this market is the access to capital. This was indicated by more than 57% of the representatives of companies in this industry. Legal regulations, including tax regulations, were indicated as the second barrier.
– In the USA, digital health start-ups are also being established, which use digital tools and mobile applications that help, for example, in the rehabilitation of people after a stroke.

  • Prev Post
  • Next Post